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expression pattern has been described in many different physiological and 
pathological conditions. In the extracellular compartments they are encapsu-
lated within vesicles, associated to proteins or apoptotic bodies. Due to their 
stability they are suggested as promising circulating biomarkers. Regarding 
pituitary adenoma several studies have been published describing the dif-
ferent expression pattern of miRNAs and their role in adenomagenesis on 
tissue level, but only a few publications investigated circulating miRNAs.
Aim
To identify pituitary tissue-specific miRNAs in circulation comparing tissue 
and blood miRNA profiles reported in literature.
Methods
Data mining of available serum or plasma miRNAs detected in patients with 
pituitary adenomas. Reevaluation of expression data and correlation with 
tumor biology.
Results
Overall, a global downregulation of miRNA expression was reported in 
plasma samples obtained from patients with pituitary adenoma compared 
to healthy controls. Pituitary adenoma tissue-specific miRNAs have low 
abundance in plasma, minimizing their role as biomarkers. To date, only 
miR-143-3p was reported as plasma maker for non-functioning adenomas 
which level decreased following surgery.
Discussion
Circulating miRNAs in pituitary adenoma would help patient care especially 
in non-functioning adenoma as minimally invasive biomarkers of tumor re-
currence and progression. However, technical difficulties may challenge the 
clinical use of miRNAs as potential biomarker and the application of stan-
dardized protocols could help their clinical utility. MiR-143-3p may predict 





Unravelling the PitNET methyloma
Antonio Pico1,2
1Department of Endocrinology & Nutrition, Hospital General Universitario 
de Alicante, Spain; 2University Miguel Hernández, Spain
Context
Pituitary tumorigenesis does not fit into the most common model of cancer 
development driven by gene mutations. Instead, epigenetic mechanisms have 
been widely involved. Among them, aberrant DNA methylation at CpG sites 
is one of epigenetic hallmarks of tumour cells. There are several methods to 
study the epigenetic regulation of genome activity, from DNA methylation 
arrays to more specific DNA methylation analysis such as pyrosequencing, 
Methylation-Specific PCR (MS-PCR) or MS-multiplex ligation-dependent 
probe amplification (MS-MLPA) of selected genes.
M & M
We studied the DNA-promoter methylation and gene expression of 35 tu-
mour suppressor genes in 105 pituitary neuroendocrine tumors (PitNETs) 
by MS-MLPA and quantitative real-time PCR techniques, looking for dif-
ferences among subtypes and between functional and invasive behaviour 
of tumors. Moreover, I revised the most relevant results published in the 
literature.
Results
We observed different methylation patterns among PitNET subtypes. The 
methylation status correlated negatively with its gene expression in some but 
not all methylated genes. Moreover, some genes appeared more frequently 
methylated in macro and invasive tumours than in micro or non-invasive 
ones. Finally, we found significant differences between functioning and 






Relapse and prediction of relapse
Erik Stenberg
Department of Surgery, Faculty of Medicine and Health, Örebro  University, 
Örebro, Sweden
Background
Over the last decade, bariatric and metabolic surgery has been recognized 
as an important step in the treatment algorithm for type-2 diabetes (T2DM). 
Despite early suggestions of surgery providing a potential cure for T2DM, 
only a small proportion of all patients who could benefit from surgery are 
ultimately considered for this treatment. Furthermore, the long-term effects 
on T2DM still remains somewhat controversial.
Methods and results
A review of the current literature as well as data from the Scandinavian 
Obesity Surgery Registry (SOReg) were considered. Remission of diabetes 
occurred for 58–89% of patients with T2DM. A higher chance of remission 
was reported for patients with shorter duration and a less severe disease. 
Age, surgical method, postoperative weight-loss, sex and socioeconomic 
status may also influence the chance of reaching remission. Relapse of dis-
ease was reported to occur in 19–50% of those who initially experienced 
remission. Longer duration and a more severe disease, as well as female 
sex, weight-regain, and type of surgery are associated with higher risk for 
relapse. Patients who eventually relapse still experience reduction in the risk 
for diabetes complications.
Conclusion
The chance of reaching diabetes remission after metabolic and bariatric sur-
gery is high. While relapse is common, patients still experience long-term 
metabolic benefits from this type of surgery.
DOI: 10.1530/endoabs.70.S3.3
Unveiling Signatures in Pituitary Neuroendocrine 
Tumours
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Circulating microRNAs: from PitNET pathogenesis to diagnostics
Henriett Butz1,2
1Department of Laboratory Medicine, Semmelweis University,  Budapest, 
Hungary; 2Department of Molecular Oncology, National Institute of 
 Oncology, Budapest, Hungary
Introduction
MicroRNAs are short, single-stranded, protein non-coding RNA molecules 
which can be secreted into the circulation by mammalian cells. Their altered 
